Mangrove Partners’s Monte Rosa Therapeutics GLUE Stock Holding History
Bought
Maintained
Sold
Other funds holding GLUE
BBA
Mangrove Partners's GLUE Position: Q3 2026 in Review
Mangrove Partners sold out of Monte Rosa Therapeutics (GLUE) in Q3 2026, closing a stake of 12,517 shares — an estimated $303K sold.
Mangrove Partners first reported a position in GLUE in Q1 2026 and held it in 2 quarters. The position peaked at $303K in Q2 2026. 190 funds tracked by Wall St. Rank hold GLUE as of Q3 2026.
- Mangrove Partners reported no remaining Monte Rosa Therapeutics position as of Q3 2026 after selling out during the quarter.
- Mangrove Partners sold 12,517 Monte Rosa Therapeutics shares in Q3 2026, an estimated $303K.
- Mangrove Partners first reported a position in Monte Rosa Therapeutics in Q1 2026 and held it in 2 quarters.
- Mangrove Partners's Monte Rosa Therapeutics position peaked at $303K in Q2 2026.
- 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2026.
Based on Mangrove Partners's 13F filing for Q3 2026, filed 16 Nov 2026.